Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours

Cerebrovascular Diseases

Volumn 19, Issue 4, 2005, Pages 260-266

  Uchino, Ken ^b   Alexandrov, Andrei V ^a   Garami, Zsolt ^a   El Mitwalli, Ashraf ^a   Morgenstern, Lewis B ^c,d   Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Safety; Stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN RADIOGRAPHY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG INFUSION; DRUG SAFETY; FATALITY; FEASIBILITY STUDY; FEMALE; HUMAN; HYPOTHESIS; LOW DRUG DOSE; MALE; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOMES RESEARCH; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEASIBILITY STUDIES; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 17844384572     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084090     Document Type: Article

References (47)

1. Kothari R, Jauch E, Broderick J, Brott T, Sauerbeck L, Khoury J, Liu T: Acute stroke: Delays to presentation and emergency department evaluation. Ann Emerg Med 1999;33:3-8.
2. Ringleb PA, Schellinger PD, Schranz C, Hacke W: Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke. Useful or harmful? Stroke 2002;33:1437-1441.
3. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
4. Kaste M, Hacke W: Desmoteplase in acute ischemic stroke (DIAS) Phase II Study Results (abstract). American Stroke Association 29th International Stroke Conference, San Diego, Calif., 2004.
5. Warach S, Davis L: ReoPro Retavase reperfusion of stroke safety study - imaging evaluation (ROSIE): Open-label, dose escalation, safety and proof of principle study of the combination of intravenous abciximab and reteplase in the treatment of acute ischemic stroke with proven perfusion defects. Ongoing Clinical Trials Session (abstract). The American Stroke Association 28th International Stroke Conference, Phoenix, Ariz., 2003.
6. Butcher KS: Echoplanar imaging thrombolysis evaluation trial: EPITHET. Ongoing Clinical Trials Session (abstract). The American Stroke Association 28th International Stroke Conference, Phoenix, Ariz., 2003.
7. Schellinger PD, Fiebach JB, Hacke W: Imaging-based decision making in thrombolytic therapy for ischemic stroke: Present status. Stroke 2003;34:575-583.
8. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderisk J, Sheppard GL, Spilker J, Kongable GL, Massey R, Reed R: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-640.
9. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR: Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-645.
10. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T: Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-2605.
11. IMS Study Investigators: Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke 2004;35:904-911.
12. Larrue V, von Kummer RR, Muller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-441.
13. Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme CT Score. Lancet 2000;355:1670-1674.
14. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF, Hansen MD: Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126-131.
15. Frankel MR, Morgenstern LB, Kwiatkowski T, Lu M, Tilley BC, Broderick JP, Libman R, Levine SR, Brott T: Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology 2000;55:952-959.
16. Johnston KC, Connors AF Jr, Wagner DP, Knaus WA, Wang X, Haley EC Jr: A predictive risk model for outcomes of ischemic stroke. Stroke 2000;31:448-455.
17. Weimar C, Ziegler A, Konig IR, Diener HC: Predicting functional outcome and survival after acute ischemic stroke. J Neurol 2002;249:888-895.
18. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T: Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-2605.
19. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, Alexandrov AV: Thrombolysis in brain ischemia (TIBI) TCD flow grades predict clinical severity, early recovery and mortality in intravenous TPA treated patients. Stroke 2001;32:89-93.
20. Alexandrov AV, Demchuk A, Wein T, Grotta JC: The yield of transcranial Doppler in acute cerebral ischemia. Stroke 1999;30:1605-1609.
21. Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D: Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999;30:1528-1533.
22. Adams HP, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ: Guidelines for the early management of patients with ischemic stroke. Stroke 2003;34:1056-1083.
23. Burgin WS, Malkoff M, Felberg RA, Demchuk AM, Christou I, Grotta JC, Alexandrov AV: Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000;31:1128-1132.
24. Haley EC, Lewandowski C, Tilley BC: Myths regarding NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med 1997;30:676-682.
25. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM: Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
26. Multicentre Acute Stroke Trial - Italy (MAST-I) Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
27. The Multicenter Acute Stroke Trial - Europe Study Group: Thrombolytic therpay with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150.
28. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR: Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276:961-966.
29. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plaminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS study: a randomized controlled trial. JAMA 1999;282:2019-2026.
30. Clark WM, Albers GW, Madden KP, Hamilton S: The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000;31:811-816.
31. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
32. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
33. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
34. Minematsu K, Yamaguchi T, Hata K, Shinohara Y, Saito I, Mori E, Nakagawa J, J-ACT Group Investigators: The results of the clinical trial of intravenous GMK-527 (alteplase) administered for ischemic stroke within 3 hours of onset (Japanese Alteplase Clinical Trial). Jpn J Stroke 2004;26:139 (in Japanese).
35. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M, PROACT Investigators: PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11.
36. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F, for the PROACT Investigators: Intra-arterial prourokinase for acute ischemic stroke: The PRO-ACT II study: A randomized controlled trial. JAMA 1999;282:2003-2011.
37. Kassem-Moussa H, Graffagnino C: Nonocclusion and spontaneous recanalization rates in acute ischemic stroke: A review of cerebral angiography studies. Arch Neurol 2002;59:1870-1873.
38. Molina CA, Montaner J, Abilleira S, Ibarra B, Romero F, Arenillas JF, Alvarez-Sabin J: Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001;32:1079-1084.
39. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
40. Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, Brott TG, Grotta J, Tilley BC, Marler JR, Frankel M: Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000;31:2335-2341.
41. Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrov AV: Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Stroke 2003;34:695-698.
42. Furlan M, Marchal G, Viader F, Derlon JM, Baron JC: Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996;40:216-226.
43. Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G: Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001;124:20-29.
44. Kilpatrick MM, Yonas H, Goldstein S, Kassam AB, Gebel JM, Wechsler LR, Jungreis CA, Fukui MB: CT-based assessment of acute stroke; CT, CT angiography, and xenon-enhanced CT cerebral blood flow. Stroke 2001;32:2543-2549.
45. Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670-1674.
46. Wintermark M, Reichhart M, Thiran JP, Maeder P, Chalaron M, Schnyder P, Bogousslavsky J, Meuli R: Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol 2002;51:417-432.
47. Alexandrov AV, Hall CE, Labiche LA, Wojner AW, Grotta JC: Ischemic stunning of the brain: Early recanalization without immediate clinical improvement in acute ischemic stroke. Stroke 2004;35:449-452.